Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition
Arcellx, Inc. (ACLX)
Company Research
Source: Business Wire
-- A more recent data cut will be shared during an oral presentation for the iMMagine-1 study ---- To date, no delayed neurotoxicities, including no Parkinsonism, no cranial nerve palsies, no Guillain-Barré syndrome, and no immune effector cell-associated enterocolitis have been observed with anito-cel ---- FDA pre-BLA meeting for anito-cel has occurred; reiterating planned 2026 commercial launch ---- Company to host a live webcast event with an expert panel of clinicians during ASH 2025 -- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced it will share two presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 6-9, 2025, in Orlando, Florida, including updated clinical data from iMMagine-1, its Phase 2 pivotal study (publication #256
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting [Yahoo! Finance]Yahoo! Finance
- Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
- Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and ExpositionBusiness Wire
ACLX
Earnings
- 11/5/25 - Miss
ACLX
Sec Filings
- 11/17/25 - Form 4
- 11/5/25 - Form 10-Q
- 11/5/25 - Form 8-K
- ACLX's page on the SEC website